Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine

Published on :

Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine GAITHERSBURG, Md., May 3, 2021 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today [….]

GSK to support manufacture of Novavax’ COVID-19 vaccine

Published on :

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK Government Vaccines Taskforce announced that they have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. GSK and Novavax will negotiate a final agreement to include additional terms and conditions.

Germantown’s QIAGEN Receives FDA Emergency Use Authorization for NeuMoDx Multiplex Test Expanding COVID-19 Portfolio

Published on :

QIAGEN Receives FDA Emergency Use Authorization for NeuMoDx Multiplex Test Expanding COVID-19 Portfolio GERMANTOWN, Md. & HILDEN, Germany–(BUSINESS WIRE)– QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Emergency [….]

Germantown’s Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

Published on :

Germantown’s Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) GERMANTOWN, Md., March 23, 2021 /PRNewswire/ — Precigen, Inc., a biopharmaceutical company specializing in the development [….]

Towson University’s new Science Complex opens

Published on :

Students returning to Towson University for spring term will find that campus has grown by 320,000 square feet.
The Science Complex is now TU’s largest academic structure—significantly larger than Smith Hall’s 220,000 square feet. It includes 50 teaching laboratories, 30 research laboratories, 50 classrooms, eight lecture halls, 10 collaborative student spaces, an outdoor classroom leading to the Glen Arboretum, a rooftop greenhouse complex, a new planetarium and an observatory.
“The completion of the new science complex marks the result of years of planning and effort from our faculty, staff and partners, including the University System of Maryland Board of Regents, Chancellor Jay A. Perman, Governor Larry Hogan and our state legislative leaders, who have shown unwavering support to this affirmation of TU’s impact on Maryland,” says President Kim Schatzel. “This impressive complex will bolster TU’s nationally-recognized STEM programming, and will enhance TU’s capacity to fulfill its promise as an anchor institution, supplying prepared leaders to meet Maryland’s workforce demands.”Read the full article at: www.towson.edu

Gaithersburg’s Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis

Published on :

Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to advancing therapies [….]